05:50 AM EDT, 03/13/2024 (MT Newswires) -- Merck ( MRK ) said Wednesday it is planning to launch clinical development of a new investigational multivalent human papillomavirus, or HPV, vaccine.

The company also said it plans to conduct clinical trials on both women and men to evaluate the safety and efficacy of its single-dose regimen of Gardasil as a way to prevent HPV-related cancer, compared with its already approved three-dose regimen.